Research progress on pyroptosis regulated by mesenchymal stem cell-derived exosomes
Yang T., An J., Xu X., Li B., Dou Z.
Narrative Review, published in Front Immunol (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Narrative Review
- Journal
- Front Immunol (2025)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 41425572
- PMCID
- PMC12711477
- DOI
- 10.3389/fimmu.2025.1717465
Abstract (original English)
Pyroptosis is a newly discovered form of inflammatory programmed cell death, which is frequently involved in the occurrence and development of various diseases. The primary mechanism underlying pyroptosis is the formation of membrane pores mediated by activated pyroptosis-related proteins. The expression levels of these pyroptosis-related proteins serve as crucial biomarkers for assessing the degree of pyroptosis. Modulating pyroptosis can alleviate tissue and organ damage in diseases and promote tissue and organ repair. Therefore, regulating pyroptosis is considered a potential therapeutic strategy. In recent years, mesenchymal stem cell-derived exosomes (MSC-Exos) have emerged as a novel therapeutic tool for pyroptosis due to their carrier properties. MSC-Exos can mitigate tissue damage in various diseases by regulating pyroptosis, thus emerging as strong candidates for disease treatment. Owing to their multifunctionality, MSC-Exos exert different effects by mediating different pathways in the treatment of various diseases. This review summarizes the mechanisms of pyroptosis and the research progress on MSC-Exos-regulated pyroptosis and outlines the existing challenges for the clinical translation of MSC-Exos. Collectively, MSC-Exos can not only precisely regulate the pyroptosis process but also provide new perspectives and approaches for future disease treatment. Therefore,
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.